Edition:
United States

ZIOPHARM Oncology Inc (ZIOP.OQ)

ZIOP.OQ on NASDAQ Stock Exchange Capital Market

5.89USD
21 Jun 2017
Change (% chg)

-- (--)
Prev Close
$5.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
304,641
52-wk High
$7.88
52-wk Low
$4.45

ZIOP.OQ

Chart for ZIOP.OQ

About

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies... (more)

Overall

Beta: 1.68
Market Cap(Mil.): $836.91
Shares Outstanding(Mil.): 142.09
Dividend: --
Yield (%): --

Financials

  ZIOP.OQ Industry Sector
P/E (TTM): -- 245.81 19.07
EPS (TTM): -1.38 -- --
ROI: -167.56 -7.82 -4.97
ROE: -- -9.67 -4.19

BRIEF-CVI Investments reports 6.8 pct passive stake in Ziopharm Oncology

* CVI Investments Inc reports a 6.8 percent passive stake in Ziopharm Oncology Inc as of May 11, 2017 - sec filing Source text - http://bit.ly/2q42eo3 Further company coverage:

May 22 2017

BRIEF-ZIOPHARM announces FDA acceptance of IND for CD33-specific CAR-T cell therapy

* Ziopharm oncology announces fda acceptance of ind for cd33-specific car-t cell therapy targeting relapsed/refractory acute myeloid leukemia

May 02 2017

BRIEF-Ziopharm Oncology reports Q1 loss per share $0.15

* Ziopharm Oncology reports first quarter 2017 financial results and provides update on recent activities

May 01 2017

BRIEF-Ziopharm appoints Amy Trevvett vice president of investor relations and corporate communications

* Ziopharm appoints Amy Trevvett vice president of investor relations and corporate communications Source text for Eikon: Further company coverage:

Mar 27 2017

BRIEF-Ziopharm Q4 loss per share $0.11

* Ziopharm reports fourth-quarter 2016 financial results and provides update on recent activities

Feb 16 2017

BRIEF-Ziopharm and Intrexon announce cooperative research and development agreement with NCI utilizing sleeping beauty system to generate T Cells targeting Neoantigens

* Ziopharm and Intrexon announce cooperative research and development agreement with the National Cancer Institute utilizing sleeping beauty system to generate T Cells targeting Neoantigens Source text for Eikon: Further company coverage:

Jan 10 2017

More From Around the Web

Earnings vs. Estimates